New Hampshire Trust Has $2.65 Million Position in Johnson & Johnson $JNJ

New Hampshire Trust reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,334 shares of the company’s stock after selling 676 shares during the quarter. New Hampshire Trust’s holdings in Johnson & Johnson were worth $2,648,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of JNJ. Apexium Financial LP grew its position in shares of Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB boosted its position in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC boosted its position in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after acquiring an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after purchasing an additional 4,816 shares in the last quarter. Finally, Klingman & Associates LLC raised its stake in shares of Johnson & Johnson by 13.4% during the 1st quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock worth $2,817,000 after purchasing an additional 2,005 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Morgan Stanley set a $190.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday, October 20th. HSBC upped their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Finally, Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 1.1%

JNJ stock opened at $190.38 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $458.69 billion, a price-to-earnings ratio of 18.38, a PEG ratio of 2.24 and a beta of 0.40. The business’s fifty day moving average price is $182.26 and its two-hundred day moving average price is $166.37. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.